A Study to Investigate the Long Term Safety, Tolerability And Effectiveness of Pf-02545920 in Subjects with Huntington's Disease Who Completed Study A8241021

Overview

About this study

The purpose of this study is an extension following study A8241021 to assess the long-term safety, tolerability and effectiveness of PF-02545920   in patients with Huntington's disease. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria

  • Must have completed study A8241021
  • Diagnosis of Huntington's disease, including ≥ 36 CAG repeats

 

Exclusion Criteria

  • Significant neurological disorder other than Huntington's disease
  • WBC ≤ 3500/mm3 
  • ANC ≤ 2000/mm3 
  • History of neutropenia or myeolo-proliferative disorders
  • Any drug related significant adverse event experienced during study A8241021 which were not approved as acceptable for enrollment in A8241022

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

John Caviness, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20169957

Mayo Clinic Footer